Construction of Nucleic Acid antibodies to PrP(sc)

Information

  • Research Project
  • 6337416
  • ApplicationId
    6337416
  • Core Project Number
    R43AG019546
  • Full Project Number
    1R43AG019546-01
  • Serial Number
    19546
  • FOA Number
  • Sub Project Id
  • Project Start Date
    5/15/2001 - 23 years ago
  • Project End Date
    10/31/2001 - 22 years ago
  • Program Officer Name
    MONJAN, ANDREW A.
  • Budget Start Date
    5/15/2001 - 23 years ago
  • Budget End Date
    10/31/2001 - 22 years ago
  • Fiscal Year
    2001
  • Support Year
    1
  • Suffix
  • Award Notice Date
    5/11/2001 - 23 years ago
Organizations

Construction of Nucleic Acid antibodies to PrP(sc)

DESCRIPTION (Applicant's abstract): We propose to develop a method for generating amplifiable nucleic acid (NA) antibodies specific for the infectious particle responsible for prion disease, PrP(sc). NA antibodies have the ability to bind proteins with high affinity and specificity. Amplifiable NA antibodies will be generated by using a variation of the SELEX procedure that takes advantage of the activity of Q-beta replicase which replaces three steps in SELEX (reverse transcription, PCR amplification and RNA transcription). Moreover, the selected sequence that encodes the protein specific binding element is contained within an RNA vector derived from a Q-beta replicase template (MNV), providing the means for exponential amplification. This new method greatly simplifies and improves upon the SELEX procedure, enabling its application in the common molecular biology laboratory. Accumulation of PrP(sc) in the brain leads to untreatable spongiform encephalitis, typically acquired through consumption of contaminated beef. Since current tests for prions takes years, and since the number of cases in the United States is on the rise, there is an urgent need for an inexpensive, rapid diagnostic assay. NA antibodies specific for PrP(sc) that are amplifiable by Q-beta replicase are ideal for the development of a highly sensitive diagnostic assay using the Company's core, proprietary technology. PROPOSED COMMERCIAL APPLICATION: Our selection process may lead to a NA antibody production service, the development of kit for sale for research purposes or the creation of a market for the enzyme, Q-beta replicase. Amplifiable NA antibodies for PrP(sc) can be used as the raw material to develop an inexpensive diagnostic assay.

IC Name
NATIONAL INSTITUTE ON AGING
  • Activity
    R43
  • Administering IC
    AG
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100060
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    866
  • Ed Inst. Type
  • Funding ICs
    NIA:100060\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    Q-RNA, INC.
  • Organization Department
  • Organization DUNS
    017527891
  • Organization City
    NEW YORK
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    10032
  • Organization District
    UNITED STATES